0001193125-26-213472
SEC filingBioAge Labs reported Q1 2026 financial results with $2.8M collaboration revenue, $22.3M net loss, and $384.9M cash supporting operations through 2029, alongside positive Phase 1 data and upcoming BGE-102 trials.
BioAge Labs' Q1 2026 results reflect accelerated investment in its lead NLRP3 inhibitor BGE-102 following positive Phase 1 data announced in April, which demonstrated best-in-class reductions in inflammatory biomarkers like hsCRP (86% median drop), IL-6, and fibrinogen, with 87-93% of participants achieving normalized hsCRP levels and a clean safety profile across doses. R&D expenses surged 84% YoY to $20.4M, driven by $5.7M in BGE-102 costs for completing the SAD/MAD trial, Phase 2 preparations in cardiovascular risk, Phase 1b/2a in DME, and manufacturing, plus $3.6M for APJ agonist programs. G&A rose 14% to $7.7M mainly from higher stock-based compensation and legal fees. Collaboration revenue doubled to $2.8M from increased Novartis FTE efforts. The $132.3M upsized follow-on offering in January/February bolstered the balance sheet to $384.9M in cash and equivalents, extending runway through 2029 and funding dual BGE-102 proof-of-concept trials starting mid-2026 (CV data YE2026, DME mid-2027) plus an APJ IND by YE2026. CEO Kristen Fortney highlighted BGE-102's potential as a 'pipeline in a pill' for cardiometabolic and ocular diseases, underscoring execution focus amid robust capital position.